Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963208 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
A Phase 3 study of Drug Resistant Partial Onset Seizure, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
- 20
- Study locations
NCT01963208 is a Phase 3 study of Drug Resistant Partial Onset Seizure that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 405 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT01963208, a Phase 3 study of Drug Resistant Partial Onset Seizure, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ganaxolone
Study Locations (20)
Alabama
- University of Alabama Epilepsy Center - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Xenoscience Inc. - Phoenix
- The MORE Foundation - Sun City
California
- Neuro-Pain Medical Center, Inc - Fresno
- Neurological Research Institute - Santa Monica
Florida
- Neuroscience Consulants - Miami
- Medsol Clinical Research Center - Port Charlotte
New Jersey
- Cooper Medical Center of Rowan University - Camden
- Northeast Regional Epilepsy Group - Hackensack
New York
- Five Towns Neuroscience Research - Cedarhurst
- Northeast Regional Epilepsy Group - Middletown
Arkansas
- Clinical Trials Inc. - Little Rock
Colorado
- University of Colorado- Anschutz Outpatient Pavilion - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963208
The ClinicalTrials.gov registry entry for NCT01963208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Resistant Partial Onset Seizure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01963208 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT01963208 about?
NCT01963208 is a clinical study titled "Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension". The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
What is the current status of trial NCT01963208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2013-10. Estimated completion is 2016-10.
What conditions does trial NCT01963208 study?
This clinical trial studies the following conditions: Drug Resistant Partial Onset Seizure.
What interventions are being tested in trial NCT01963208?
The interventions under investigation include: Placebo (DRUG), ganaxolone (DRUG).
Who is sponsoring clinical trial NCT01963208?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01963208 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.